Biotech veteran Art Krieg explains the science behind his newest immunotherapy company, Zola Therapeutics, which uses both RNA and DNA agonists delivered in an LNP to create broad T-cell responses
Interviewed by fellow veteran Jim Barsoum, Dr. Krieg shares multi-decade learnings from his previous companies Coley Pharmaceutical Group and Checkmate Pharmaceuticals, and describes how Zola builds off of that. He explains the importance of combining agonists to TLR9 to TLR7 and TLR8, and also describes the virtual set-up that the company has today.
--------
40:48
Elias Zerhouni and Andy Plump discuss the future of multispecific biologics
Interviewed by Andy Plump, President of R&D at Takeda, Dr. Zerhouni discusses the rationale for multispecifics and the science behind them. They also discuss the differences between pharma and biotech, keys to being an effective R&D leader, and advice for both young and experienced people in their careers.
--------
35:49
Candel Therapeutics CEO Paul Peter Tak and IDEA Pharma CEO Mike Rea on why they believe a different mindset and good communication are keys to succeeding with new innovations in biotech
They discuss the difference between how biotech companies operate from large pharmas, including how history shows some new biotech innovations faced initial development and market pushback, and how good communication typically played a key role in why some overcame hurdles vs others. Plus, a description of Candel's viral immunotherapy approach.Note: IDEA Pharma and Candel have a business relationship (as discussed).
--------
31:12
Korro Bio's Ram Aiyar and Novo Nordisk's Uli Stilz discuss their RNA editing collaboration, the field of genetic medicine, and the future of drug discovery
Ram Aiyar, President & CEO of Korro Bio, and Uli Stilz, Head of Novo Nordisk's Bio Innovation Hub in Kendall Square, share their backgrounds and the scope of their work today. They discuss their RNA editing collaboration and how both the smaller and larger companies bring difference skills to these kinds of partnerships. Plus, their visions of what drug discovery might look like ten years from now.
--------
30:49
Devan Shah and Namita Bisaria, experts in the field of RNA therapies, discuss the year ahead in RNA - opportunities, challenges, AI, fundraising, and more
Devan Shah, Founder & CEO of RNAV8 Bio, and Namita Bisaria, Head of Research, Strategy, and Operations at AIRNA, discusses approaches to RNA they are excited about this year, companies that have impressed them, and challenges ahead. They touch on uncertainties regarding the regulatory environment, how they think AI might, or might not, affect the field, and more.
The Studio at Kendall Square is a video podcast studio built by BiotechTV and MassBio at MassBio's headquarters in Tech Square at Kendall Square. It is a platform for the Boston biotech community to use and have your podcast discussions recorded in-person and then broadcast on BiotechTV. The studio will give voice to the vast network of experts who live in and around 'The Most Innovative Square Mile on the Planet'.
España